Literature DB >> 7822317

Proline-directed and non-proline-directed phosphorylation of PHF-tau.

M Morishima-Kawashima1, M Hasegawa, K Takio, M Suzuki, H Yoshida, K Titani, Y Ihara.   

Abstract

To gain insight into the abnormal phosphorylation of PHF-tau, we have determined the phosphorylation sites by identifying phosphopeptides by means of ion spray mass spectrometry followed by sequencing of ethane-thiol-modified peptides. Nineteen sites have been identified; all but Ser-262 are localized to the amino- and carboxyl-terminal flanking regions of the microtubule-binding domain. Eleven sites correspond to fetal type sites. Unexpectedly, 10 are non-proline-directed, whereas the others are proline-directed. Thus, the abnormal phosphorylation of PHF-tau can be considered to consist of fetal type phosphorylation and additional proline-directed and non-proline-directed phosphorylation. This non-fetal type phosphorylation may provide PHF-tau with the unusual characteristics.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822317     DOI: 10.1074/jbc.270.2.823

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  149 in total

1.  Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

Authors:  N Matsumura; T Yamazaki; Y Ihara
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 2.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Tau dephosphorylation at tau-1 site correlates with its association to cell membrane.

Authors:  M Arrasate; M Pérez; J Avila
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

4.  Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities.

Authors:  F J Ekinci; T B Shea
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

5.  Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons.

Authors:  S E Merrick; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

6.  Tau protein expression in adult bovine oligodendrocytes: functional and pathological significance.

Authors:  Hanna Ksiezak-Reding; Muhammad Farooq; Liang-sheng Yang; Dennis W Dickson; Patrizia LoPresti
Journal:  Neurochem Res       Date:  2003-09       Impact factor: 3.996

7.  [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].

Authors:  A Schneider; P Falkai; A Papassotiropoulos
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

Review 8.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

10.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.